<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eflapegrastim: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eflapegrastim: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eflapegrastim: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="139677" href="/d/html/139677.html" rel="external">see "Eflapegrastim: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57290224"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rolvedon</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57211660"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Colony Stimulating Factor;</li>
<li>
                        Hematopoietic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F57256559"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56029a5f-b8b9-48b1-93d5-9b4bee4853bc">Chemotherapy-induced neutropenia, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced neutropenia, prevention: SUBQ:</b> 13.2 mg once per chemotherapy cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32687266','lexi-content-ref-32476162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32687266','lexi-content-ref-32476162'])">Ref</a></span>). Administer ~24 hours after cytotoxic chemotherapy. Do not administer within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57256561"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function prior to treatment initiation: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Nephrotoxicity during treatment: Glomerulonephritis (suspected): If glomerulonephritis is suspected, evaluate for cause; if likely due to eflapegrastim, consider dose reduction or treatment interruption.</p></div>
<div class="block doha drugH1Div" id="F57256562"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F57256563"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Acute respiratory distress syndrome: Discontinue eflapegrastim.</p>
<p style="text-indent:-2em;margin-left:2em;">Allergic reactions, serious: Permanently discontinue eflapegrastim.</p>
<p style="text-indent:-2em;margin-left:2em;">Aortitis (suspected): Discontinue eflapegrastim if aortitis is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">Capillary leak syndrome: Monitor closely and manage symptomatically if capillary leak syndrome develops (may require intensive care).</p>
<p style="text-indent:-2em;margin-left:2em;">Sickle cell crisis: Discontinue eflapegrastim if sickle cell crisis occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">WBC ≥100,000/mm<sup>3</sup>: Discontinue eflapegrastim.</p></div>
<div class="block doe drugH1Div" id="F57256560"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F57409626"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute myeloid leukemia and myelodysplastic syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute myeloid leukemia and myelodysplastic syndrome have been reported with filgrastim, another granulocyte-colony stimulating factor product, when used in conjunction with chemotherapy and/or radiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26450505','lexi-content-ref-20385991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26450505','lexi-content-ref-20385991'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Aortitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aortitis has been rarely reported in patients receiving other granulocyte-colony stimulating factor (G-CSF) products (eg, filgrastim, pegfilgrastim), commonly presenting with systemic symptoms (eg, high fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein, white blood cell count) rather than peripheral vasculitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33598604','lexi-content-ref-34530312','lexi-content-ref-32188815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33598604','lexi-content-ref-34530312','lexi-content-ref-32188815'])">Ref</a></span>). Aortitis recurrence with re-administration of G-CSF following aortitis resolution has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33598604','lexi-content-ref-32188815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33598604','lexi-content-ref-32188815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not fully elucidated; may be related to cytokines and complex immune reactions between anti-cancer agents and G-CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33598604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33598604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of 8 days and mean time to onset of 12.3 days (range: 0 to 180 days) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33598604','lexi-content-ref-34530312','lexi-content-ref-32188815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33598604','lexi-content-ref-34530312','lexi-content-ref-32188815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Capillary leak syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, have been reported in patients who received granulocyte-colony stimulating factor (G-CSF) products. CLS episodes may vary in frequency and severity and may be life-threatening if treatment is delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7517230','lexi-content-ref-35096191','lexi-content-ref-30404164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7517230','lexi-content-ref-35096191','lexi-content-ref-30404164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not fully elucidated; one study suggests G-CSF may trigger neutrophil activation and the release of inflammatory mediators, resulting in tissue damage and systemic manifestations of increased capillary permeability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35663724','lexi-content-ref-21422685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35663724','lexi-content-ref-21422685'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; has been reported within a few hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35096191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35096191'])">Ref</a></span>) or over the course of 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7517230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7517230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute respiratory distress syndrome, respiratory status deterioration (including acute respiratory failure), and exacerbation of preexisting pulmonary disease have been reported with granulocyte-colony stimulating factor (G-CSF) products and may be life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35115328','lexi-content-ref-15937498','lexi-content-ref-34232946','lexi-content-ref-10352330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35115328','lexi-content-ref-15937498','lexi-content-ref-34232946','lexi-content-ref-10352330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not fully elucidated; G-CSF enhancement of cytokine production (eg, TNF-α, IL-1β, and IL-8) increases alveolar permeability and neutrophil influx by activation of the oxidative burst within circulating or resident alveolar neutrophils and macrophages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35115328','lexi-content-ref-15937498','lexi-content-ref-34232946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35115328','lexi-content-ref-15937498','lexi-content-ref-34232946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; has been reported within 1 day (range: 0.5 to 2 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15937498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15937498'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• ≥3 courses of cancer chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15937498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15937498'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Neutropenia recovery period (including early or steep neutrophil recovery period) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15937498','lexi-content-ref-34232946','lexi-content-ref-10352330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15937498','lexi-content-ref-34232946','lexi-content-ref-10352330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent history of pulmonary infiltrates or pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34232946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34232946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pulmonary infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10352330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10352330'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Splenic enlargement and rupture</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Spleen enlargement and splenic rupture, including fatal cases, have been reported with other granulocyte-colony stimulating factor (G-CSF) products (eg, filgrastim, pegfilgrastim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29330272','lexi-content-ref-32276997','lexi-content-ref-23907972','lexi-content-ref-35638556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29330272','lexi-content-ref-32276997','lexi-content-ref-23907972','lexi-content-ref-35638556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not fully elucidated; it has been speculated that large increase of immature myeloid cell density (mainly granulocyte precursors) in the spleen through extra medullar hematopoiesis may cause splenic rupture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29330272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29330272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset has been reported &lt;2 weeks after G-CSF initiation (range: 3 to 13 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29330272','lexi-content-ref-32276997','lexi-content-ref-23907972','lexi-content-ref-35638556','lexi-content-ref-17276841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29330272','lexi-content-ref-32276997','lexi-content-ref-23907972','lexi-content-ref-35638556','lexi-content-ref-17276841'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57227646"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (18%), skin rash (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17%), decreased appetite (19%), diarrhea (40%), nausea (52%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (25%), thrombocytopenia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (16%), fatigue (58%), headache (29%), pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (21%), back pain (20%), lower leg pain (11%), myalgia (22%), ostealgia (38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (15%), dyspnea (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (28%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Cardiovascular: Flushing (10%)</p></div>
<div class="block coi drugH1Div" id="F57211548"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of serious allergic reactions (eg, anaphylaxis) to eflapegrastim, pegfilgrastim, filgrastim, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57256542"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: Serious allergic reactions (including anaphylaxis) may occur with granulocyte colony-stimulating factor (G-CSF) products, such as eflapegrastim.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: WBC counts of ≥100,000/mm<sup>3</sup> have been reported with G-CSF products. Thrombocytopenia has also been reported with G-CFS products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Based on findings of azotemia, hematuria (micro- and macroscopic), proteinuria, and renal biopsy, glomerulonephritis has occurred in patients receiving G-CSF products. Evaluate for cause if glomerulonephritis is suspected. Glomerulonephritis usually resolved after eflapegrastim dose reduction or discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disorders: Severe and sometimes fatal sickle cell crises may occur in patients with sickle cell disorders receiving G-CSF products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor growth effects: The G-CSF receptor through which G-CSF products act has been found on tumor cell lines. G-CSF products may possibly act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia.</p></div>
<div class="block foc drugH1Div" id="F57290225"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rolvedon: Eflapegrastim-xnst 13.2 mg/0.6 mL (0.6 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F57290223"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509864"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Rolvedon Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.2 mg/0.6 mL (per 0.6 mL): $5,400.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57256564"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer the entire contents of the prefilled syringe SUBQ. The syringe does not have graduation marks and is intended to deliver the entire contents upon administration. Place sealed blister pack tray on a clean, flat surface and allow tray to reach room temperature for at least 30 minutes prior to use; do not warm syringe any other way. Do not shake. Do not use prefilled syringe if it is dropped onto a hard surface (use a new syringe for the dose).</p></div>
<div class="block use drugH1Div" id="F57211547"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of chemotherapy-induced neutropenia:</b> To decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Eflapegrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic cell transplantation.</p></div>
<div class="block mst drugH1Div" id="F57256539"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Eflapegrastim may be confused with filgrastim, pegfilgrastim, sargramostim, tbo-filgrastim.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57229830"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57229827"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan.  Management: Do not administer granulocyte colony-stimulating factor (G-CSF) until at least 24 hours after completion of belotecan administration. Monitor neutrophil counts and signs/symptoms of neutropenic fever in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may interact via an unknown mechanism with Betibeglogene Autotemcel.  Management: Granulocyte-colony stimulating factor is not recommended for 21 days after betibeglogene autotemcel infusion.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of bleomycin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Topotecan. Specifically, the risk for the development of interstitial lung disease may be increased. Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of topotecan. Additionally, monitor patients closely for the development of interstitial lung disease with this combination.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F57256540"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in reproduction studies conducted in rabbits and rats at doses up to 10 and 7 times the maximum human dose, respectively, based on AUC.</p></div>
<div class="block brc drugH1Div" id="F57256541"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if eflapegrastim is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Eflapegrastim is a recombinant granulocyte colony-stimulating factor (G-CSF). Endogenous G-CSF and other recombinant G-CSFs are present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57256566"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor CBC (including platelets) during therapy. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain. Evaluate for acute respiratory distress syndrome in patients who develop fever and lung infiltrates or respiratory distress. Monitor for signs/symptoms of allergic reactions, glomerulonephritis, aortitis, and capillary leak syndrome. Monitor for signs/symptoms of myelodysplastic syndromes and acute myeloid leukemia.</p></div>
<div class="block pha drugH1Div" id="F57256552"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Eflapegrastim is a long-acting recombinant human granulocyte growth factor conjugated with a recombinant human IgG Fc fragment with the Fc fragment allowing for an extended half-life (Cobb 2020; Schwartzberg 2020). Eflapegrastim binds to granulocyte colony-stimulating factor receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways to cell differentiation, proliferations, migration, and survival.</p></div>
<div class="block phk drugH1Div" id="F57256553"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 1.44 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Eflapegrastim is internalized by cells bearing the granulocyte-colony stimulating factor receptor and expected to be metabolized via endogenous degradation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: 36.4 hours (range: 16.1 to 115 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 25 hours (range: 6 to 144 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Not detected in urine.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29330272">
<a name="29330272"></a>Benguerfi S, Thepault F, Lena H, Ricordel C. Spontaneous splenic rupture as a rare complication of G-CSF injection. <i>BMJ Case Rep</i>. 2018;2018:bcr2017222561. doi:10.1136/bcr-2017-222561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/29330272/pubmed" id="29330272" target="_blank">29330272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26450505">
<a name="26450505"></a>Calip GS, Malmgren JA, Lee WJ, Schwartz SM, Kaplan HG. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. <i>Breast Cancer Res Treat</i>. 2015;154(1):133-143. doi:10.1007/s10549-015-3590-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/26450505/pubmed" id="26450505" target="_blank">26450505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32276997">
<a name="32276997"></a>Chinaka UC, Fultang J, Pereca J, Ali A. Atraumatic idiopathic splenic rupture induced by granulocyte-colony stimulating factor (G-CSF) for the treatment of pancytopenia, managed successfully by laparoscopic splenectomy. <i>BMJ Case Rep</i>. 2020;13(4):e232411. doi:10.1136/bcr-2019-232411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/32276997/pubmed" id="32276997" target="_blank">32276997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32687266">
<a name="32687266"></a>Cobb PW, Moon YW, Mezei K, et al. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): a phase 3 study. <i>Cancer Med</i>. 2020;9(17):6234-6243. doi:10.1002/cam4.3227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/32687266/pubmed" id="32687266" target="_blank">32687266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35115328">
<a name="35115328"></a>Doig C, Cooke R, Chua C, Leung T. Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed <i>Pneumocystis jirovecii</i> pneumonia. <i>BMJ Case Rep</i>. 2022;15(2):e242316. doi:10.1136/bcr-2021-242316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/35115328/pubmed" id="35115328" target="_blank">35115328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23907972">
<a name="23907972"></a>Fernandes LR, dos Santos CL, Costa F, Barata F. Spontaneous splenic rupture in a patient with small-cell lung cancer. <i>BMJ Case Rep</i>. 2013;2013:bcr2013010325. doi:10.1136/bcr-2013-010325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/23907972/pubmed" id="23907972" target="_blank">23907972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35663724">
<a name="35663724"></a>Gotera N, Hasan S, Shrestha P, Heleno C, Tesar A. A case of concurrent leukocytosis and systemic capillary leak syndrome due to pegfilgrastim. <i>Cureus</i>. 2022;14(5):e24640. doi:10.7759/cureus.24640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/35663724/pubmed" id="35663724" target="_blank">35663724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33598604">
<a name="33598604"></a>Harada M, Motoki H, Sakai T, Kuwahara K. Granulocyte colony stimulating factor-associated aortitis evaluated via multiple imaging modalities including vascular echography: a case report. <i>Eur Heart J Case Rep</i>. 2020;5(2):ytaa503. doi:10.1093/ehjcr/ytaa503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/33598604/pubmed" id="33598604" target="_blank">33598604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34530312">
<a name="34530312"></a>Hoshina H, Takei H. Granulocyte-colony stimulating factor-associated aortitis in cancer: a systematic literature review. <i>Cancer Treat Res Commun</i>. 2021;29:100454. doi:10.1016/j.ctarc.2021.100454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/34530312/pubmed" id="34530312" target="_blank">34530312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15937498">
<a name="15937498"></a>Karlin L, Darmon M, Thiéry G, et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. <i>Bone Marrow Transplant</i>. 2005;36(3):245-250. doi:10.1038/sj.bmt.1705037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/15937498/pubmed" id="15937498" target="_blank">15937498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385991">
<a name="20385991"></a>Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. <i>J Clin Oncol</i>. 2010;28(17):2914-2924. doi:10.1200/JCO.2009.25.8723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/20385991/pubmed" id="20385991" target="_blank">20385991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35638556">
<a name="35638556"></a>Markovic U, Colarossi C, Iuppa A, et al. Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review. <i>J Int Med Res</i>. 2022;50(5):3000605221095504. doi:10.1177/03000605221095504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/35638556/pubmed" id="35638556" target="_blank">35638556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422685">
<a name="21422685"></a>Nakagawa N, Ota H, Tanabe Y, et al. A case of idiopathic systemic capillary leak syndrome with high serum levels of G-CSF on exacerbation. <i>Intern Med</i>. 2011;50(6):597-600. doi:10.2169/internalmedicine.50.4857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/21422685/pubmed" id="21422685" target="_blank">21422685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7517230">
<a name="7517230"></a>Oeda E, Shinohara K, Kamei S, Nomiyama J, Inoue H. Capillary leak syndrome likely the result of granulocyte colony-stimulating factor after high-dose chemotherapy. <i>Intern Med</i>. 1994;33(2):115-119. doi:10.2169/internalmedicine.33.115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/7517230/pubmed" id="7517230" target="_blank">7517230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rolvedon.1">
<a name="Rolvedon.1"></a>Rolvedon (eflapegrastim) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32476162">
<a name="32476162"></a>Schwartzberg LS, Bhat G, Peguero J, et al. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. <i>Oncologist</i>. 2020;25(8):e1233-e1241. doi:10.1634/theoncologist.2020-0105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/32476162/pubmed" id="32476162" target="_blank">32476162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34232946">
<a name="34232946"></a>Shalata W, Waichenberg L, Massalha I, Dudnik Y, Rouvinov K, Yakobson A. Pulmonary toxicity following administration of granulocyte colony-stimulating factor during chemotherapy for breast cancer: a case report and literature review. <i>Anticancer Drugs</i>. 2021;32(10):1142-1145. doi:10.1097/CAD.0000000000001115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/34232946/pubmed" id="34232946" target="_blank">34232946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35096191">
<a name="35096191"></a>Sharie AHA, Zu'bi YOA, Sharie SA, et al. Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report. <i>Memo</i>. 2022;15(2):143-148. doi:10.1007/s12254-021-00789-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/35096191/pubmed" id="35096191" target="_blank">35096191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30404164">
<a name="30404164"></a>Shin JI, Lee KH, Lee IR, et al. Systemic capillary leak syndrome (Clarkson syndrome) in cancer patients: a systematic review. <i>J Clin Med</i>. 2018;7(11):418. doi:10.3390/jcm7110418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/30404164/pubmed" id="30404164" target="_blank">30404164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32188815">
<a name="32188815"></a>Shirai T, Komatsu H, Sato H, Fujii H, Ishii T, Harigae H. Migratory aortitis associated with granulocyte-colony-stimulating factor. <i>Intern Med</i>. 2020;59(12):1559-1563. doi:10.2169/internalmedicine.4331-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/32188815/pubmed" id="32188815" target="_blank">32188815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10352330">
<a name="10352330"></a>Takahashi Y, Kobayashi Y, Chikayama S, Ikeda M, Kondo M. Effect of granulocyte/colony-stimulating factor on the onset of the adult respiratory distress syndrome. <i>Acta Haematol</i>. 1999;101(3):124-129. doi:10.1159/000040937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/10352330/pubmed" id="10352330" target="_blank">10352330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17276841">
<a name="17276841"></a>Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. <i>Am J Emerg Med</i>. 2007;25(2):247-248. doi:10.1016/j.ajem.2006.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eflapegrastim-drug-information/abstract-text/17276841/pubmed" id="17276841" target="_blank">17276841</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139627 Version 29.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
